NASDAQ$AVDL
Avadel Pharmaceuticals plc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported third quarter results with no revenue due to sale of sterile injectable products and net loss increase due to decline in revenue. Advanced FT218 toward anticipated FDA approval.
Avadel Pharmaceuticals reported no revenue for Q3 2020 due to the sale of sterile injectable products. R&D expenses were $5.6 million, and SG&A expenses were $8.4 million. The net loss for the quarter was $11.7 million, or ($0.20) per diluted share. Cash, cash equivalents, and marketable securities were $231.6 million as of September 30, 2020.
- No revenue reported for Q3 2020 due to the sale of sterile injectable products.
- R&D expenses decreased to $5.6 million compared to $7.5 million in Q3 2019.
- SG&A expenses increased to $8.4 million compared to $5.3 million in Q3 2019.
- Net loss for Q3 2020 was $11.7 million, or ($0.20) per diluted share.
Headline financials
Revenue & EPS history
Avadel · Revenue · Quarterly
$0
Revenue by segment
Avadel · $7M total across 1 segment · Q3 2023
- LUMRYZ Net Product Revenue$7M—100.0%
Forward guidance
The Company remains on track to submit the filing to the FDA by the end of December for FT218.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports
-1.2%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+2.3%
Avg return
30 days after
44%
28 / 64 earnings
Positive
+22.2%
Q4 2020
Best reaction
-26.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.4% | -1.0% | +12.9% | |
| Q2 2025 | +14.7% | +20.7% | +42.0% | |
| Q1 2025 | +9.1% | +10.5% | +12.1% | |
| Q4 2024 | -4.6% | +0.1% | -5.6% | |
| Q3 2024 | -26.3% | -33.1% | -34.9% | |
| Q2 2024 | -3.7% | +0.8% | -9.9% | |
| Q1 2024 | -12.9% | -7.8% | -16.9% | |
| Q4 2023 | +15.2% | +19.2% | +18.7% | |
| Q3 2023 | +6.9% | — | — | |
| Q2 2023 | -0.6% | — | — | |
| Q1 2023 | +5.4% | — | — | |
| Q4 2022 | +3.0% | — | — | |
| Q3 2022 | -0.3% | — | — | |
| Q2 2022 | +13.2% | — | — | |
| Q1 2022 | -5.0% | — | — | |
| Q4 2021 | +4.7% | — | — | |
| Q3 2021 | +7.3% | — | — | |
| Q2 2021 | -3.4% | — | — | |
| Q1 2021 | +1.1% | — | — | |
| Q4 2020 | +22.2% | — | — | |
| Q3 2020 | +11.7% | — | — | |
| Q2 2020 | -7.4% | — | — | |
| Q1 2020 | -2.5% | — | — | |
| Q4 2019 | -24.8% | — | — | |
| Q3 2019 | -2.7% | — | — | |
| Q2 2019 | -11.4% | — | — | |
| Q1 2019 | -3.3% | — | — | |
| Q4 2018 | -15.0% | — | — | |
| Q3 2018 | -25.6% | — | — | |
| Q2 2018 | -11.5% | — | — | |
| Q1 2018 | +4.0% | — | — | |
| Q4 2017 | -11.0% | — | — | |
| Q3 2017 | -1.3% | — | — | |
| Q2 2017 | -5.2% | — | — | |
| Q1 2017 | +1.6% | — | — | |
| Q4 2016 | +6.0% | — | — | |
| Q3 2016 | -2.8% | — | — | |
| Q3 2015 | -2.8% | — | — | |
| Q2 2016 | +1.0% | — | — | |
| Q1 2016 | +1.4% | — | — | |
| Q4 2015 | +1.6% | — | — | |
| Q2 2015 | -10.8% | — | — | |
| Q1 2015 | +6.0% | — | — | |
| Q4 2014 | -0.3% | — | — | |
| Q3 2014 | +0.2% | — | — | |
| Q2 2014 | +1.3% | — | — | |
| Q1 2013 | +3.4% | — | — | |
| Q1 2014 | +3.4% | — | — | |
| Q4 2013 | +2.3% | — | — | |
| Q3 2012 | -1.2% | — | — | |
| Q3 2013 | -1.2% | — | — | |
| Q2 2013 | -5.0% | — | — | |
| Q4 2012 | +1.4% | — | — | |
| Q2 2011 | +6.0% | — | — | |
| Q2 2012 | +6.0% | — | — | |
| Q1 2011 | -1.1% | — | — | |
| Q4 2011 | -4.8% | — | — | |
| Q4 2009 | -4.8% | — | — | |
| Q4 2010 | -4.8% | — | — | |
| Q1 2012 | -4.5% | — | — | |
| Q3 2011 | -5.0% | — | — | |
| Q3 2010 | -0.7% | — | — | |
| Q2 2010 | -6.9% | — | — | |
| Q1 2010 | -4.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro